CoChat

Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective

Moeller, Lars C, Führer, Dagmar · 2013 · Endocrine-Related Cancer

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Abstract

Thyroid hormones (THs) may play a role in diseases other than hyper- and hypothyroidism. Several lines of evidence suggest tumor-promoting effects of TH and TH receptors. They are possibly mediated by phosphatidylinositol-3-kinase and MAPK and involve among others stimulation of angiogenesis via αvβ3. Thus, an increased risk for colon, lung, prostate, and breast cancer with lower TSH has been demonstrated in epidemiological studies, even suggesting a TH dose effect on cancer occurrence. Furthermore, higher TH levels were associated with an advanced clinical stage of breast and prostate cancer. In rodent models, TH stimulated growth and metastasis of tumor transplants, whereas hypothyroidism had opposite effects. In clinical studies of glioblastoma and head and neck cancer, hypothyroid patients showed longer survival than euthyroid patients. Also, patients with renal cell cancer that were treated with the tyrosine kinase inhibitor sunitinib and developed hypothyroidism in due course showed significantly longer survival than patients that remained euthyroid. Development of hypothyroidism was an independent predictor for survival in two studies. Yet, it is still possible that hypothyroidism is only a surrogate marker for treatment efficacy and does not positively influence treatment outcome by itself. Future cancer treatment studies, especially with substances that can induce hypothyroidism, should therefore be designed in a way that allows for an analysis of thyroid function status and its contribution on treatment outcome.

Overview

Integrity signals

Registry

Crossref · 10.1530/erc-12-0219

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 79 references

Research works printed but not linked: 1

  1. Speranza G Rubinstein L Ivy SP Harris PJ 2011 Correlation between adverse event reports of hypothyroidism and clinical response in patients treated with vascular endothelial growth factor receptor inhibitors (VEGFR-I). Journal of Clinical Oncology29(Supplement: ASCO Meeting Abstracts Part 1) abstract 2602 · doi:10.1200/jco.2011.29.15_suppl.2602

Cited by

See all 184

Metadata

Authors
Moeller, L. C., & Führer, D.
Affiliations
University of Duisburg-Essen (DE)
Venue
Endocrine-Related Cancer
Published
2013-04-01
Volume
20
Issue
2
Pages
R19-R29
ISSN
  • 1351-0088 (ISSN-L)
  • 1479-6821
OpenAlex
W2128280017
Cited by
184
References
76
Citations by year
2026: 7 · 2025: 14 · 2024: 16 · 2023: 14 · 2022: 18 · 2021: 18 · 2020: 15 · 2019: 19 · 2018: 13 · 2017: 10 · 2016: 14 · 2015: 18 · 2014: 8
FWCI
1.95
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine Related Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
thyroid hormones, thyroid hormone receptor, cancer, hypothyroidism, tumor promotion, phosphatidylinositol 3-kinase, MAPK signaling, angiogenesis, alpha v beta 3 integrin, thyroid-stimulating hormone, colon cancer, lung cancer, prostate cancer, breast cancer, glioblastoma, head and neck cancer, renal cell carcinoma, sunitinib, tyrosine kinase inhibitors, cancer survival, metastasis
MeSH terms
Animals, Disease Models, Animal, Humans, Neoplasms, Receptors, Thyroid Hormone, Thyroid Hormones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. https://app.cochat.ai/papers/10.1530/erc-12-0219
The paper
Moeller, L. C., & Führer, D. (2013). Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. Endocrine-Related Cancer. https://doi.org/10.1530/erc-12-0219

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.